WilmerHale represented the joint-book running managers in the initial public offering of 5,000,000 shares of common stock of Entasis Therapeutics Holdings Inc. for aggregate gross proceeds of $75.0 million. The offering priced on September 25, 2018 at $15.00 per share and closed on September 28, 2018.
The WilmerHale team representing the underwriters was led by Lisa Firenze and included Scott Lunin, Sean Linnehan, and Jasmine Haddad (capital markets); Bruce Manheim (FDA); Colleen Superko (intellectual property); Bill Caporizzo, Rich Andersen, Kim Wethly, Meghan Walsh, Ciara Baker and Ben Kelsey (tax); and Heidi Treiber (Nasdaq and FINRA matters).